{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:39:32Z","timestamp":1787236772125,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K18465"],"award-info":[{"award-number":["JP20K18465"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K10170"],"award-info":[{"award-number":["JP21K10170"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral Biosciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.job.2025.100682","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T11:48:48Z","timestamp":1753530528000},"page":"100682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of anti-RANKL and anti-PD-1 antibodies on cancer-induced osteolysis in mice"],"prefix":"10.1016","volume":"67","author":[{"given":"Po-Chin","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2099-7293","authenticated-orcid":false,"given":"Akiko","family":"Karakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hosonuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-3367","authenticated-orcid":false,"given":"Yuki","family":"Azetsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kamikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3042-0753","authenticated-orcid":false,"given":"Aoi","family":"Oshio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1002-1775","authenticated-orcid":false,"given":"Masahiro","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-3975","authenticated-orcid":false,"given":"Masamichi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.job.2025.100682_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.job.2025.100682_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"Suppl","key":"10.1016\/j.job.2025.100682_bib3","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1097\/01.blo.0000093840.72468.e1","article-title":"Prostate cancer and bone metastases: medical treatment","volume":"415","author":"Clark","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.job.2025.100682_bib4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"David Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.job.2025.100682_bib5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.job.2025.100682_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.job.2025.100682_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.job.2025.100682_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41413-020-00105-1","article-title":"Molecular mechanisms and clinical management of cancer bone metastasis","volume":"8","author":"Wang","year":"2020","journal-title":"Bone Res"},{"key":"10.1016\/j.job.2025.100682_bib11","first-page":"449","article-title":"A new member of tumor necrosis factor ligand family","volume":"256","author":"Takahashi","year":"1999","journal-title":"ODF\/OPGL\/TRANCE\/RANKL, regulates osteoclast differentiation and function"},{"key":"10.1016\/j.job.2025.100682_bib12","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.job.2025.100682_bib13","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ajpath.2013.01.038","article-title":"RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer","volume":"182","author":"Sato","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.job.2025.100682_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.job.2025.100682_bib15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jcb.20958","article-title":"Regulation of osteoblast differentiation by transcription factors","volume":"99","author":"Komori","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.job.2025.100682_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrrheum.2014.164","article-title":"Fracture healing: mechanisms and interventions","volume":"11","author":"Einhorn","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.job.2025.100682_bib17","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.job.2025.100682_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jso.23654","article-title":"Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases","volume":"110","author":"Ratasvuori","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.job.2025.100682_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.job.2025.100682_bib20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298","volume":"15","author":"Coxon","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.job.2025.100682_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.job.2025.100682_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","article-title":"Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis","volume":"48","author":"Lipton","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.job.2025.100682_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Roussy","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.job.2025.100682_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrclinonc.2011.197","article-title":"Denosumab in patients with cancer-a surgical strike against the osteoclast","volume":"9","author":"Brown","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.job.2025.100682_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1152\/physiol.00020.2022","article-title":"RANKL and RANK in cancer therapy","volume":"38","author":"Onji","year":"2023","journal-title":"Physiology"},{"key":"10.1016\/j.job.2025.100682_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s13063-019-3951-x","article-title":"Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B\/2, translational trial (POPCORN)","volume":"20","author":"Ahern","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.job.2025.100682_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.job.2025.100682_bib28","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.job.2025.100682_bib29","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.21037\/jtd-21-150","article-title":"Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors","volume":"13","author":"Cao","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.job.2025.100682_bib30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.job.2025.100682_bib31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.job.2025.100682_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.job.2025.100682_bib34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bone.2004.06.018","article-title":"The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis","volume":"35","author":"Nagahama","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.job.2025.100682_bib35","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1172\/JCI133334","article-title":"PD-1 blockade inhibits osteoclast formation and murine bone cancer pain","volume":"130","author":"Wang","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.job.2025.100682_bib36","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nature05656","article-title":"Nuclear cytokine-activated IKK\u03b1 controls prostate cancer metastasis by repressing Maspin","volume":"446","author":"Luo","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib38","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1101\/gad.304162.117","article-title":"RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer","volume":"31","author":"Rao","year":"2017","journal-title":"Genes Dev"},{"key":"10.1016\/j.job.2025.100682_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.job.2024.02.003","article-title":"Tacrolimus, FK506, promotes bone formation in bone defect mouse model","volume":"66","author":"Nishida","year":"2024","journal-title":"J Oral Biosci"},{"key":"10.1016\/j.job.2025.100682_bib42","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.job.2025.100682_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3857\/roj.2012.30.2.70","article-title":"Method of tumor volume evaluation using magnetic resonance imaging for outcome prediction in cervical cancer treated with concurrent chemotherapy and radiotherapy","volume":"30","author":"Kim","year":"2012","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.job.2025.100682_bib44","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1172\/JCI42528","article-title":"Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation","volume":"120","author":"Nishikawa","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1016\/j.job.2025.100682_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-59677-1","article-title":"Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody","volume":"14","author":"Murayama","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.job.2025.100682_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109821","article-title":"Bone metastatic mammary tumor cell-derived extracellular vesicles inhibit osteoblast maturation via JNK signaling","volume":"750","author":"Uehara","year":"2023","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.job.2025.100682_bib47","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.3390\/ijms20246342","article-title":"Cancer cell-derived granulocyte-macrophage colony-stimulating factor is dispensable for the progression of 4T1 murine breast cancer","volume":"20","author":"Yoshimura","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.job.2025.100682_bib48","first-page":"5438","article-title":"Receptor activator of nuclear factor-\u03baB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.job.2025.100682_bib49","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.bjc.6600858","article-title":"Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis","volume":"88","author":"Ohshiba","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.job.2025.100682_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature14403","article-title":"A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis","volume":"520","author":"Wagenblast","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.job.2025.100682_bib51","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.3390\/cancers13174310","article-title":"Bone metastatic breast cancer: advances in cell signaling and autophagy related mechanisms","volume":"13","author":"Othman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.job.2025.100682_bib52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/gene.2013.29","article-title":"Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL","volume":"14","author":"Walsh","year":"2013","journal-title":"Gene Immun"},{"key":"10.1016\/j.job.2025.100682_bib53","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12998\/wjcc.v12.i18.3555","article-title":"Cytokine release syndrome triggered by programmed death 1 blockade (sintilimab) therapy in a psoriasis patient: a case report","volume":"12","author":"Zhou","year":"2024","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.job.2025.100682_bib54","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.12998\/wjcc.v12.i35.6782","article-title":"Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: a dark side of immune checkpoint inhibitors","volume":"12","author":"Maldonado-Garc\u00eda","year":"2024","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.job.2025.100682_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115755","article-title":"Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption","volume":"143","author":"Monteiro","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.job.2025.100682_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040729","article-title":"Mouse preclinical cancer immunotherapy modeling involving anti\u2010pd\u20101 therapies reveals the need to use mouse reagents to mirror clinical paradigms","volume":"13","author":"Monjazeb","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Oral Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1349007925000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1349007925000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:41:29Z","timestamp":1772764889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1349007925000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1349007925000714"],"URL":"https:\/\/doi.org\/10.1016\/j.job.2025.100682","relation":{},"ISSN":["1349-0079"],"issn-type":[{"value":"1349-0079","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of anti-RANKL and anti-PD-1 antibodies on cancer-induced osteolysis in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.job.2025.100682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Association for Oral Biology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100682"}}